NewsBenzinga파브메드 자회사 루시드 다이그노스틱스, 에소가드(EsoGuard)를 활용한 비내시경성 식도 전암 검사 임상 결과 발표···2분 이내 에소체크셀(EsoCheckCell) 수집의 효율성과 확장성 입증 파브메드 자회사 루시드 다이그노스틱스, 에소가드(EsoGuard)를 활용한 비내시경성 식도 전암 검사 임상 결과 발표···2분 이내 에소체크셀(EsoCheckCell) 수집의 효율성과 확장성 입증 Benzinga 2026.11.03 13:17 (GMT+0) Open on Benzinga Other news OpenAI Details NATO Use of Its Cybersecurity Models 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen